JIAN SHU

shujian@nwu.edu.cn

 

 DETAILS                                                     

Address:      School of Medicine, Faculty of Life Science & Medicine, Northwest University, No. 229 Taibai Beilu, Xi’an 710069, Shaanxi Province, China.

Email:          shujian@nwu.edu.cn

Website :      https://orcid.org/0000-0002-2938-4218

                      Web of Science (clarivate.cn)

 

RESEARCH INTERESTS                                            

l  Cancer diagnosis and Salivary diagnostics: Detection of cancer and development of diagnostic tools based on salivary glycopatterns data and machine learning algorithms.

l  Salivary glycopatterns for natural regulation of oral microbiota: Investigation of the relationship between salivary glycoproteins and oral microorganisms, and to explore the regulatory mechanism

 

WORK EXPERIENCE                                             

Lecturer (June 2023 - present)

School of Medicine, Faculty of Life Science & Medicine

Northwest University Shaanxi, Xi’an China

Post-doc (July 2020 - June 2023)

College of Life Sciences, Faculty of Life Science & Medicine

Northwest University Shaanxi, Xi’an China

 

EDUCATIONAL                                                 

College of Life Sciences, Northwest University, Xi’an, China

PhD, Biochemistry and molecular biology                              Sep 2017-June 2020

Research title：The relationship between neoglycoproteins and oral microbiota in gastric cancer patients, Supervisors     Prof. Zheng Li

 

College of Life Sciences, Northwest University, Xi’an, China

MSc, Biochemistry and molecular biology                              Sep 2014-June 2017

Research title: The Aberrant Glycosylation of Salivary Protein in Gastric Cancer Patients, Supervisors     Prof. Zheng Li

 

College of Life Sciences, Northwest University, Xi’an, China

BSc, National base for Life Science and Technology             Sep 2010-June 2014

 

FOUNDATION                                                                                                                      

l  National Natural Science Foundation of China (NSFC), 32101030, (1/2022-12/2024) (In research, Leader)

      l  Scientific Research Program Funded by Shaanxi Provincial Education Department, (Proram No, 23JK0687), (1/2023-12/2024) (In research, Leader)

l  Natural Science Basic Research Program of Shaanxi, 2021JQ-446, (1/2021-12/2022) (Concluded, Leader)

l  Northwest University Excellent Doctoral Dissertation Cultivation Project, YYB17018, (10/2017-6/2020) (Concluded, Leader)

l  NSFC, 81871955, (1/2019-12/2022) (Concluded, Participant)

l  NSFC, 81773180, (1/2018-12/2021) (Concluded, Participant)

l  NSFC, 21705127 (1/2018-12/2020) (Concluded, Participant)

l  NSFC, 81670577 (1/2017-12/2020) (Concluded, Participant)

 

PUBLICATUONS (H-index=10)                                                     

l Dang J#, Shu J^#,*, Wang R, Yu H, Chen Z, Yan W, Zhao B, Ding L, Wang Y, Hu H^*, Li Z^*. The glycopatterns of Pseudomonas aeruginosa as a potential biomarker for its carbapenem resistance, Microbiology Spectrum, 2023, DOI: https://doi.org/10.1128/spectrum.02001-23  (Co-first/Co-corresponding  author)

l  J Shu, X Ren, H Cheng, et al. Beneficial or detrimental: Recruiting more types of benign cases for cancer diagnosis based on salivary glycopatterns, International Journal of Biological Macromolecules, 2023, https://doi.org/10.1016/j.ijbiomac.2023.126354. (IF=8.2, Top)

l  J Shu, H Yu, X Ren, et al. Role of salivary glycopatterns for oral microbiota associated with gastric cancer, International Journal of Biological Macromolecules, 2022, 209:1368-1378. (IF=8.2, Top)

l  X Ren^#, J Shu^#, J Wang, et al. Machine learning reveals salivary glycopatterns as potential biomarkers for the diagnosis and prognosis of papillary thyroid cancer, International Journal of Biological Macromolecules, 2022, 215:280-289. (IF=8.2, Top, Co-first author)

l  J Shu, J Ma, X Ren, et al. The Abnormal Glycopatterns of Salivary Glycoproteins in Esophageal Squamous Cell Carcinoma Patients, Frontiers in Chemistry, 2021, 9(62):637730. (IF=5.545)

l  H Yu^#, J Shu^#, Z Li. Lectin microarrays for glycoproteomics: an overview of their use and potential [J]. Expert Review of Proteomics, 2020; 17(1): 27-39.

l  J Shu, L Dang, D Zhang, et al. Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line [J]. FEBS Journal. 2019; 286(8):1594-1605. (IF=4.390)

l  J Shu, H Yu, H Du, et al. Identification of N- and O-linked glycans recognized by AAL in saliva of patients with atrophic gastritis and gastric cancer[J]. Cancer biomarkers, 2018; 22(4): 669-681.

l  J Shu, H Yu, X Li, et al. Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer[J]. Oncotarget. 2017,8(22):16082.

l  J Shu, H Yu, X Liu, et al. New progress of glycoprotein glycans associated with gastric cancer[J]. Progress in Biochemistry & Biophysics, 2016, 43(5):449-460.

l  X Liu, H Yu, Y Qiao, J Yang, J Shu, et al. Salivary glycopatterns as potential biomarkers for screening of early-stage breast cancer[J]. EBioMedicine, 2018, 28, 70-79.

l  J Yang, X Liu, J Shu, et al. Abnormal Galactosylated–Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer. Glycoconjugate Journal, 2020, 37, 373-394.

l  H Zhu, M Liu, H Yu, X Liu, Y Zhong, J Shu, et al. Glycopatterns of urinary protein as new potential diagnosis indicators for diabetic nephropathy. J Diabetes Res, 2017, 2017:5728087.

l  J Zhang, Y Zhong, P Zhang, H Du, J Shu, et al. Identification of abnormal fucosylated-glycans recognized by LTL in saliva of HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Glycobiology, 2019,29(3):242-259.

l  Q Jian, Z Yang, J Shu, et al. Lectin BS‐I inhibits cell migration and invasion via AKT/GSK‐3β/β‐catenin pathway in hepatocellular carcinoma, Journal of cellular and molecular medicine, 2018, 22 (1), 315-329

INVENTION                                                                      

Ø  ZL202110984286.1,        (China, Authorization date: 2023-06-06)

Ø  ZL202110910586.5,        (China, Authorization date: 2023-04-07)

Ø  ZL202010062124.8,        (China, Authorization date: 2023-03-24)

Ø  ZL202010059785.5,        (China, Authorization date: 2023-02-10)

Ø  ZL202010397235.4,        (China, Authorization date: 2022-12-23)

Ø  ZL201910074569.5,        (China, Authorization date: 2021-10-22)

Ø  ZL201811277891.X,       (China, Authorization date: 2021-06-25)

Ø  ZL201711369378.9,       (China, Authorization date: 2019-12-03)

Ø  ZL201611073359.7,        (China, Authorization date: 2018-10-30)

Ø  ZL201610007829.3,        (China, Authorization date: 2018-05-04)

Ø  ZL 201610123938.1,       (China, Authorization date: 2017-12-01)

Ø  ZL201610315822.8,        (China, Authorization date: 2017-12-01)

SOFTWARE                                                                  

Ø  Registration NO.: 2018R11L720814

Ø  Registration NO.: 2018R11L081301

Ø  Registration NO.: 2018R11L224025

Ø  Registration NO.: 2017R11L121971

OTHERS                                                

Editorial Review Board: Technology in Cancer Research & Treatment

Peer Review:  Emerging Microbes & Infections

                        International Journal of Biological Macromolecules